TOTAL MIGRAINE FREEDOM FOR BREATH POWERED INTRANASAL DELIVERY OF 22 MG SUMATRIPTAN POWDER (AVP-825) VERSUS 100 MG ORAL SUMATRIPTAN FROM THE COMPASS STUDY OF ACUTE TREATMENT OF MIGRAINE

被引：0

作者：

Halker, R. ^{[1
]}

Tepper, S. ^{[2
]}

Siegert, S. ^{[3
]}

Wallick, C. ^{[3
]}

机构：

[1] Mayo Clin Phoenix, Scottsdale, AZ USA

[2] Cleveland Clin, Cleveland, OH 44106 USA

[3] Avanir Pharmaceut Inc, Aliso Viejo, CA USA

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 03期

关键词：

D O I：

10.1016/j.jval.2015.03.1627

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PND7

引用

页码：A278 / A278

页数：1

共 46 条

[1] Total Migraine Freedom for Breath Powered Intranasal Delivery of 22 Mg Sumatriptan Powder (AVP-825) versus 100 Mg Oral Sumatriptan from the COMPASS Study of Acute Treatment of Migraine
Halker, R.
Tepper, S. J.
Siegert, S.
Wallick, C.
[J]. HEADACHE, 2015, 55 : 136 - 136
[2] Total migraine freedom for breath powered intranasal delivery of 22mg sumatriptan powder (AVP-825) versus 100mg oral sumatriptan from the compass study in acute migraine
Halker, R.
Tepper, S.
Siegert, S.
Wallick, C.
Shulman, K.
[J]. CEPHALALGIA, 2015, 35 : 22 - 22
[3] Consistency of response in the compass study [breath powered intranasal delivery of 22mg sumatriptan powder (AVP-825) versus 100mg oral sumatriptan in acute migraine
Lipton, R.
Buse, D.
Shulman, K.
Siffert, J.
Siegert, S.
[J]. CEPHALALGIA, 2015, 35 : 22 - 23
[4] CONSISTENCY OF RESPONSE IN THE COMPASS STUDY [BREATH POWERED™ NASAL DELIVERY OF 22 MG SUMATRIPTAN POWDER (AVP-825) VERSUS 100 MG ORAL SUMATRIPTAN IN ACUTE MIGRAINE: A COMPARATIVE CLINICAL TRIAL]
Lipton, Richard B.
Buse, Dawn C.
Shulman, Ken
Siffert, Joao
Siegert, Scott
[J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2015, 30 : S128 - S128
[5] Consistency of Response in Acute Treatment of Migraine: The COMPASS Study of Breath-Powered Intranasal Delivery of Sumatriptan Powder (AVP-825) Versus Oral Sumatriptan
Lipton, Richard B.
Buse, Dawn C.
Shulman, Ken
Siffert, Joao
Siegert, Scott
[J]. ANNALS OF NEUROLOGY, 2015, 78 : S93 - S93
[6] Total Migraine Freedom for Breath Powered Intranasal Delivery System Containing 22 mg Suniatriptan Powder (AVP-825) vs 100 mg Oral Suniatriptan from the COMPASS Study of Acute Treatment of Migraine
Halker, Rashmi
Tepper, Stewart
Shulman, Kenneth
Wallick, Christopher
[J]. NEUROLOGY, 2016, 86
[7] AVP-825 Breath-Powered Intranasal Delivery System Containing 22mg Sumatriptan Powder vs 100mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks
Tepper, Stewart J.
Cady, Roger K.
Silberstein, Stephen
Messina, John
Mahmoud, Ramy A.
Djupesland, Per G.
Shin, Paul
Siffert, Joao
[J]. HEADACHE, 2015, 55 (05): : 621 - 635
[8] AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine
Silberstein, Stephen
[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 821 - 832
[9] COMPASS Study: Benefits of AVP-825 vs Oral Sumatriptan on Treating Migraine Pain
Lipton, Richard B.
McGinley, James
Siffert, Joao
Shulman, Kenneth J.
Siegert, Scott
Buse, Dawn C.
[J]. ANNALS OF NEUROLOGY, 2015, 78 : S93 - S93
[10] Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan
Silberstein, Stephen
Winner, Paul K.
McAllister, Peter J.
Tepper, Stewart J.
Halker, Rashmi
Mahmoud, Ramy A.
Siffert, Joao
[J]. HEADACHE, 2017, 57 (06): : 862 - 876

← 1 2 3 4 5 →